Google News

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron  Structure TherapeuticsStructure Therapeutics reports significant weight loss from mid-stage GLP-1 pill  statnews.comThis biotech is working on a GLP-1 pill that could be better than the Wegovy version  MarketWatchStructure touts 16% weight loss for aleniglipron as 'highest efficacy' for an oral GLP-1 yet  Fierce BiotechStructure Therapeutics reports more Phase 2 data for oral GLP-1  Endpoints News